January 8, 2021
Gmail users: to ensure you're always viewing the entire newsletter, check at the bottom of the email to see if the newsletter has been "clipped" and click "view entire message" if so.
Member/Center Highlights
Researchers aim artificial intelligence at rising oral cancers with $3.3M grant from National Cancer Institute
From The Daily: Researchers at Case Western Reserve University and partners in the United States and India are applying the investigative and predictive capabilities of artificial intelligence (AI) to help physicians customize treatments for patients with oral squamous cell carcinomas.
Research shows that oral squamous cell carcinomas cancer is already the eighth-most common type worldwide and numbers are steadily increasing in the United States, India and other parts of Asia.

The National Cancer Institute awarded a five-year, $3.3 million grant to a group led by Anant Madabhushi, PhD, the Donnell Institute Professor of Biomedical Engineering at Case Western Reserve and head of the Center for Computational Imaging and Personalized Diagnostics (CCIPD), and James Lewis Jr., MD, a professor of pathology, microbiology and immunology at Vanderbilt University Medical Center. Dr. Madabhushi is a member of the Case Comprehensive Cancer Center.
Recommended Reading: Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group meeting summary
In August 2020, the Prostate Cancer Foundation convened a working group to meet and discuss biomarkers for hormone-sensitive prostate cancer, the proceedings of which are summarized in this recently published article. This meeting covered the state of clinical and biological evidence for systemic therapies in the mHSPC space, with emphasis on charting a course for the generation, interrogation, and clinical implementation of biomarkers for treatment selection. This review article summarizes the work presented and discussed in the meeting with the hope that sharing this information will engage the broader prostate cancer research community in the effort to identify and validate clinically meaningful biomarkers that improve the treatment of men presenting with mHSPC.
Accepting applications: Cancer-focused Summer Undergraduate Research Program
The Cancer-focused Summer Undergraduate Research Program (CanSUR) helps highly motivated undergraduates prepare for the next stage of their careers through work with Case CCC researchers over the course of a 10-week program.

CanSUR is accepting applications through January 15, 2021.
Security Notice: Submissions to the Case Comprehensive Cancer Center
Recent security measures across the Cleveland Clinic network have made the Case CCC Marketing and Communications Request Form inaccessible to members of our community.

The current submission form is currently being recreated on another platform and will be announced when it is complete. While the existing form is still available for use on private networks or mobile devices with browsing data, requests and submissions may also be sent directly to our communications team for review at cancer@case.edu in the interim. We apologize for the inconvenience and are working to resolve the issue as soon as possible.
What's Coming Up
Mark Your Calendar
Cancer Center Seminar Series
TODAY, January 8, 2021, 12p via Zoom
Our series returns again virtually for Spring 2021 today, Friday, January 8 at 12 pm. Hannelore Heemers, PhD will present, "Alternative Treatment Strategies for Prostate Cancer" on behalf of the Case Comprehensive Cancer Center's GU Malignancies Program.

Dr. Heemers is associate staff at the Center for GU Malignancies Research, Cleveland Clinic Lerner Research Institute, and an adjunct assistant professor in the Department of Molecular Medicine at Case Western Reserve University School of Medicine. The Heemers laboratory research program focuses on generating insights into the specific molecular mechanisms by which the androgen receptor drives prostate cancer progression.
Cancer Center Seminar Series
Friday, January 15, 2021, 12p via Zoom
Next week's Cancer Center Seminar features Jae Jung, PhD presenting, "TRIM56: Intracellular DNA Sensing Pathway and Nonalcoholic Fatty Liver Disease," on behalf of the Molecular Oncology Program.

Dr. Jung is Betsy DeWindt Chair, Department of Cancer Biology and Director, Global and Emerging Pathogen Research Center at Cleveland Clinic Lerner Research Institute and member of the Case CCC's Molecular Oncology Program. Dr. Jung’s lab has shown that TRIM25 induces the K63-linked ubiquitination of RIG-I RNA sensor and TRIM56 induces the mono-ubiquitination of cGAS (cyclic GMP-AMP synthase) DNA sensor, which both are critical for cytosolic viral nucleic sensing to induce host’s anti-viral innate immunity. On the other hand, his lab has also found that TRIM56 targets and stabilizes AMP kinase pathway to regulate fatty acid synthesis. TRIM56 deficient mice develop obesity and nonalcoholic fatty liver disease (NAFLD), a condition in which excess fat is stored in the liver, leading to cirrhosis and liver cancer. This indicates that TRIM56 may link cGAS-mediated DNA sensing with NAFLD.
Registration Now Open: Cancer Disparities Symposium (Virtual)
March 4-5, 2021

The Case Comprehensive Cancer Center Office of Community Outreach and Engagement is pleased to present the 5th Annual Cancer Disparities Symposium, Navigating Cancer Disparities: Lessons Learned and How to Move Forward.
Registration is now open for this multi-disciplinary event for researchers, clinicians, health professionals, community outreach groups, community-based organizations, patient advocates and trainees. Keynote presentations will be delivered by renowned disparities researchers and community leaders, and a poster session highlighting academic research and community programs will provide a showcase of the depth and depth of work happening in this field.

Though the symposium is happening virtually, attendees will experience the conference using Whova, our official web-based conference app, to view presentations and ask questions in real-time, as well as network with others behind the scenes.

Call for Abstracts: Deadline January 22
Multidisciplinary researchers, community agencies and organizations are invited to submit abstracts for presentation at the 5th Annual Cancer Disparities Symposium. Abstracts will be divided into two tracks: Scientific Research and Community Programs. Meritorious abstracts will be selected for pre-recorded presentations. Abstracts must be submitted electronically by 5 pm ET on Friday, January 22, 2021.
Keynote Speakers Announced
Otis W. Brawley, MD, an internationally-recognized expert in cancer prevention and control, will present the symposium's Scientific Keynote His work is focused on closing racial, economic and social disparities in prevention, detection and treatment of cancer in the United States and worldwide.

Worta McCaskill-Stevens, MD, a medical oncologist nationally known for her expertise in bringing clinical trials to the community will present the Community Keynote. Dr. McCaskill-Stevens is Chief of the Community Oncology and Prevention Trials Research Group, which houses the National Cancer Institute (NCI) Community Oncology Research Program (NCORP), a community-based clinical trials network launched in 2014.
Additional Upcoming Events
AACR
AACR Virtual Meeting: COVID-19 and Cancer
Meeting: February 3-5, 2021
Join thought leaders from academia, government, and industry for AACR’s 2021 COVID-19 and Cancer virtual meeting. Emerging data in basic, clinical, and epidemiologic research related to COVID-19 and cancer will be presented in a mix of keynote lectures, forums, and symposia.

Session topics include:
  • Biology of COVID-19 and Cancer
  • Cancer Prevention and Early Detection
  • Continuity of Cancer Care
  • Critical Care and Outpatient Management
  • Effects of Cancer Treatments on COVID-19
  • Health Inequities and Disparities
  • Immunology and Pathogenesis
  • Long-term Effects and Survivorship
  • Risk Factors and Comorbidities 
  • Trials in Progress
  • Vaccines
NCCN 2021 Virtual Congress™: Breast Cancer with Updates from the 2020 San Antonio Breast Cancer Symposium (SABCS)
Friday, February 12, 2021
Breast cancer continues to be the second most common cause of cancer death in women in the United States. Results from numerous clinical trials continue to expand diagnostic/prognostic tools, therapeutic options, and supportive care strategies. Healthcare professionals need to be educated on current and emerging scientific data to make evidence-based treatment decisions and to provide optimal care for patients with breast cancer.

The NCCN 2021 Virtual Congress™: Breast Cancer with Updates from the 2020 San Antonio Breast Cancer Symposium (SABCS) will provide expert insights on the current standard of care for patients with breast cancer and include the latest clinical research updates from the 2020 SABCS to assist clinicians in formulating breast cancer management strategies.
4th Annual International PTEN Symposium
Monday, March 15, 2021
The Genomic Medicine Institute and Center for Personalized Genetic Healthcare at Cleveland Clinic invite you to join the virtual 4th Annual International PTEN Symposium: From Patient-Centered Research to Clinical Care. They are planning an engaging day with an emphasis on advances in the diagnosis, management and treatment of patients with PTEN Hamartoma Tumor Syndrome (PHTS).

Pier Paolo Pandolfi, MD, PhD, FRCP, senior scientist at the Renown Institute for Cancer and honorary professor of molecular biology at the University of Turin, will deliver the morning keynote address. Neil Friedman, MBChB, pediatric neurologist and director of quality, outcomes, and innovation at Barrow Neurological Institute at Phoenix Children’s Hospital, will deliver the afternoon keynote address on the neurological spectrum of PHTS. Other topics include hormone use and high-risk patients, gynecological cancer risks, updates on PTEN clinical trials, and autism. Please refer to the symposium agenda for more details about this year’s speakers and topics.
AACI Clinical Research Innovation 13th Annual Meeting
July 13-15, 2021
Save the date! The 13th Annual AACI Clinical Research Innovation (CRI) Meeting will be held July 13-15, 2021. Information about the meeting format, abstract submissions, and registration will be made available in early 2021.
Funding Opportunities
AACR
AACR
The inaugural AACR-Exelixis Renal Cell Carcinoma Research Fellowship represents a joint effort to encourage and support postdoctoral or clinical research fellows to conduct renal cell carcinoma research and to establish a successful career path in this field. The research proposed for funding may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to renal cell carcinoma.

This fellowship provides a two-year grant of $120,000 to support the salary and benefits of the fellow while working on mentored renal cell carcinoma research. A partial amount of funds may be designated for non-personnel expenses, such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, and other research expenses.
The Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine represents a joint effort to encourage and support postdoctoral or clinical research fellows to conduct highly novel and provocative research in the field of regenerative cancer medicine and to establish a successful career path in this field. The research proposed for funding may be translational, clinical, or epidemiological in nature and must have direct applicability and relevance to enhancing the physiology or function of cancer survivors using regenerative medicine techniques.

This award provides a two-year grant of $120,000 to support the salary and benefits of the fellow while working on mentored research focused on regenerative cancer medicine. A partial amount of funds may be designated for non-personnel expenses, such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, and other research expenses. Indirect costs are not permitted.
This is the first year of the fourth phase of the Case-Coulter Translational Research Partnership (CCTRP) to support collaborative translational research projects that address unmet or poorly met clinical needs. The CCTRP seeks to reduce the market risk of promising new clinical products arising from the research programs of BME and affiliated Case faculty. Successful projects will thus often focus on the development of prototype products, building relationships with companies, performing clinical feasibility studies, obtaining regulatory approval, and other activities that companies or business experts indicate are the essential last steps before a license can be negotiated or a startup launched. An overarching goal of the program is to foster research and development work likely leading to commercially relevant translational technologies within a three- to five-year horizon. Because the goals of all Coulter projects are to reduce market risk, all proposals are expected to reflect genuine business input, and all projects must include a “business advisor” as an important member of the decision-making team.

The CCTRP awards funding at 2 different levels, pilot and full projects:

Pilot Projects
Pilot projects up to $25,000 can be applied for on a rolling basis but will be considered quarterly. Pilot projects will typically be for a six-month period with specific milestones defined with the intent of participation in the annual full Coulter award cycle. Apply using the same instructions with a focus on the necessary steps that will position PI for a successful full CCTRP application the following year. The individual component sections can be scaled back, but the PI is responsible for making his/her case. There are no CCTRP OC presentations for pilot projects.
Full Projects
Full projects will typically be for an initial one-year period with specific milestones defined on a quarterly basis; in special circumstances, proposals can span more than one year but must be approved prior to submission. Continuation and renewal applications will be evaluated on a competitive basis with new applications, and must have a comparison of milestones achieved vs. those planned in the original award. An important part of the proposal is the commercialization opportunity and the idea or vision for the end product. Examples of preferred future outcomes include inventions, patents, improved diagnosis and treatment of disease, commercial products, licenses, commercial partnerships and start-up companies.
In The News
Cleveland Magazine - January 4, 2021
The Cleveland Clinic president and CEO oversees more than 2.4 million patient visits each year. A career cardiac surgeon, Mihaljevic helped build and served as the CEO of the Cleveland Clinic in Abu Dhabi before taking on his position in Cleveland.
Science Magazine - January 5, 2021
Researchers at Case Western Reserve University, led by Anant Madabushi, PhD, and partners in the United States and India are applying the investigative and predictive capabilities of artificial intelligence (AI) to help physicians customize treatments for patients with oral squamous cell carcinomas.
From The NIH
Request for Information (RFI) regarding opportunities for new national programs at the National Cancer Institute’s (NCI) Frederick National Laboratory for Cancer Research
NCI has released a Request for Information (RFI) seeking input from the cancer research community on the most important needs and promising opportunities in cancer research that are difficult to address on an individual scale but could be tackled through the NCI Frederick National Laboratory for Cancer Research. This is part of a planning effort to identify unique, large-scale programs of national significance that the FNLCR could support in the interest of the entire cancer research community.

Email responses to RFI_NewNationalPrograms@nih.gov and place "RFI Response" in the subject line. Responses will be accepted through January 18, 2021.
Weekly NIH Funding Opportunities and Notices
COVID-19 Funding Opportunities and Notices
Have something to share?
Use the button below to submit all your news, publications, events, announcements, lab openings and communications requests to the Case CCC Marketing and Communications team! We are here to help.